Article
In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 1 Feb 2012
Kamburova E G, Koenen H J P M, Boon L, Hilbrands L B, Joosten I
Abstract excerpt
Rituximab is a chimeric anti-CD20 monoclonal antibody (mAb) used in B-cell malignancies, various autoimmune disorders and organ transplantation. Although administration of a single dose of rituximab results in full B-cell depletion in peripheral blood, there remains a residual B-cell population in secondary lymphoid organs. These nondepleted B cells might be altered by exposure to rituximab with subsequent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.